**Lay Report**

We are conducting a clinical trial in which people with pre-treated HR+ metastatic breast cancer are randomized 1:1 to receive sacituzumab govitecan with pembrolizumab or sacituzumab govitecan alone. The trial is almost done enrolling participants; we only need to enroll one more to reach the accrual target of 110 participants. We will compare the effectiveness of the two treatments in terms of progression-free survival, overall survival, and objective response rate.

We performed research biopsies to collect tumor tissue from each participant before they started therapy (baseline) and during the first few weeks of therapy (on-treatment). Each participant may also undergo an optional third research biopsy at the time of disease progression (end of treatment with experimental therapy).

We are preparing baseline, on-treatment, and optional end of treatment tumor tissue for a variety of analyses, including: o Evaluating the type, number, location, and gene expression patterns of immune cells within the tumors. o Analyzing protein expression within tumor cells to look for signs of DNA damage and repair. o Analyzing the genome sequence and genome-wide patterns of gene expression within tumor cells.

The results of these analyses will be compared with clinical outcomes to evaluate the mechanisms behind the effectiveness (or lack thereof) of each treatment.